In fact, SREBP itself and all expressed proteins in lipid metabolism (ACCs, ACLY, FASN, LDLR, etc.)constitute potential cancer targets, and the respective inhibitors are already tested in preclinical and phase 1 trials [196,233]. This evidence concerns the gene ACLY and cancer.